Skip to main content
SpringerLink
Log in

The Regulation of C1 Activation and Its Role in Disease

  • Chapter
Therapeutic Interventions in the Complement System

Part of the book series: Contemporary Immunology ((CONTIM))

  • 126 Accesses

Abstract

Inflammatory reactions contribute to the pathogenesis of numerous diseases. These reactions result from the release and activation of endogenous inflammatory mediators, such as cytokines and the major plasma cascade systems. The latter include the coagulation, fibrinolytic, contact, and complement systems. Proinflammatory activity of the complement system is mainly attributable to the release of peptide fragments, such as the anaphylatoxin, and the generation of macromolecular protein complexes, such as the C5b-9 complexes, during activation. Modulation of the biological effects of these complement activation products constitutes a therapeutic option in human disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cooper, N. R. (1985) The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 37, 151–216.

    Article  PubMed  CAS  Google Scholar 

  2. Schumaker, V. N., Zavodsky, P., and Poon, P. H. (1987) Activation of the first component of complement. Annu. Rev. Immunol. 5, 21–42.

    Article  PubMed  CAS  Google Scholar 

  3. Ziccardi, R. J. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. J. Immunol. (1982) 128, 2500–2504.

    PubMed  CAS  Google Scholar 

  4. Ziccardi, R. J. (1982) A new role for C1-inhibitor in homeostasis: control of activation of the first component of human complement. J. Immunol. 128, 2505–2508.

    PubMed  CAS  Google Scholar 

  5. Ziccardi, R. J. and Cooper, N. R. (1979) Active dissassembly of the first complement component, C1, by C1 -inactivator. J. Immunol. 123, 788–792.

    PubMed  CAS  Google Scholar 

  6. Hack, C. E., Hannema, A. J., Eerenberg, A. J. M., Out, T. A., and Aalberse, R. C. (1981) A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J. Immunol. 127, 1450–1453.

    PubMed  CAS  Google Scholar 

  7. Thijs, L. G., Hack, C. E., Strack van Schijndel, R. J. M., et al. (1989) Complement activation and high-dose of interleukin-2. Lancet 2, 395.

    Article  PubMed  CAS  Google Scholar 

  8. Thijs, L. G., Hack, C. E., Strack van Schijndel, R. J. M., et al. (1990) Activation of the complement system during immunotherapy with recombinant interleukin-2: relation to the development of side effects. J. Immunol. 144, 2419–2424.

    PubMed  CAS  Google Scholar 

  9. Baars, J. W., Hack, C. E., Wagstaff, J., et al. (1992) The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br. J. Cancer 65, 96–101.

    Article  PubMed  CAS  Google Scholar 

  10. Eikelenboom, P. and Stam, F. C. (1982) Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. 57, 239–242.

    Article  PubMed  CAS  Google Scholar 

  11. Eikelenboom, P., Hack, C. E., Rozemuller, J. M., and Stam, F. C. (1989) Complement activation in amyloid plaques in Alzheimer’s dementia. Virchows Arch. 56, 259–262.

    CAS  Google Scholar 

  12. Rogers J, Cooper NR, Webster S, et al. (1992) Complement activation by β-amyloid in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 89, 10,016–10,020.

    Article  PubMed  CAS  Google Scholar 

  13. Pinckard, R. N., Olson, M. S., Kelley, R. E., et al. (1973) Antibody-independent activation of human C1 after interaction with heart subcellular membranes. J. Immunol. 110, 1376–1382.

    PubMed  CAS  Google Scholar 

  14. Kagiyama, A., Savage, H. E., Michael, L. H., Hanson, G., Entman, M. L., and Rossen, R. D. (1989) Molecular basis of complement activation in ischemic myocardium: identification of specific molecules of mitochondrial origin that bind human Clq and fix complement. Circ. Res. 64, 607–615.

    Article  PubMed  CAS  Google Scholar 

  15. Ying, S.-C., Gewurz, A. T., Jiang, H., and Gewurz, H. (1993) Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14–26 and 76–92 of the A chain collagen-like region of C1q. J. Immunol. 150, 169–176.

    PubMed  CAS  Google Scholar 

  16. Volanakis, J. E. (1982) Complement activation by C-reactive protein complexes. Ann. NY Acad. Sci. 389, 235–249.

    Article  PubMed  CAS  Google Scholar 

  17. Kilpatrick, J. M. and Volanakis, J. E. (1994) Molecular genetics, structure, and function of C-reactive protein. Immunol. Res. (1991) 10, 43–53.

    Article  Google Scholar 

  18. Steel, D. M. and Whitehead, A. S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today 15, 81–88.

    Google Scholar 

  19. Wolbink, G. J., Brouwer, M. C., Buysmann, S., Ten Berge, R. J. M., and Hack, C. E. (1996) CRP-mediated activation of complement in vivo: assessment by measuring circulating complement complexes. J. Immunol. 157, 473–479.

    PubMed  CAS  Google Scholar 

  20. Bruins, P., Te Velthuis, H., Yazdanbakhsh, A. P., et al. (1997) Activation of the complement system during and after cardiopulmonary bypass surgery. Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96, 3542–3548.

    Article  PubMed  CAS  Google Scholar 

  21. Wolbink, G. J., Bossink, A. W. J., Groeneveld, A. B. J., de Groot, M. C. M., ThiJs, L. G., and Hack, C. E. (1998) Complement activation in patients with sepsis is in part mediated by C-reactive protein. J. Infect. Dis. 177, 81–87.

    Article  PubMed  CAS  Google Scholar 

  22. Lagrand, W. K., Niessen, H. W. M., Wolbink, G. J., et al. (1997) C-reactive protein and complement co-localize in the human heart after ischemia. Circulation 95, 97–103.

    Article  PubMed  CAS  Google Scholar 

  23. Hack, C. E., Wolbink, G. J., Schalkwijk, C., Speijer, H., Hermens, W. T., and Van den Bosch, H. (1997) A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol. Today 18, 111–115.

    Article  PubMed  CAS  Google Scholar 

  24. Zachowski A. (1993) Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem. J. 294, 1–14.

    PubMed  CAS  Google Scholar 

  25. Higgins, C. F. (1994) Flip-flop the transmembrane translocation of lipids. Cell 79, 393–395.

    Article  PubMed  CAS  Google Scholar 

  26. Jiang, H., Robey, F. A., Gewurz, H. (1992) Localization of sites through which C-reactive protein binds and activates complement to residues 14–26 and 76–92 of the human C1q A chain. J. Exp. Med. 175, 1373–1379.

    Article  PubMed  CAS  Google Scholar 

  27. Jiang, H., Siegel, J. N.,and Gewurz, H. (1991) Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J. Immunol. 146, 2324–2330.

    PubMed  CAS  Google Scholar 

  28. Jiang, H., Burdick, D., Glabe, C. G., Cotman, C. W., Tenner, A. J. β-Amyloid activates complement by binding to a specific region of the collagenlike domain of the C1q A chain. J. Immunol. (1994) 152, 5050–5059.

    PubMed  CAS  Google Scholar 

  29. Travis, J. and Salvesen, G. S. (1983) Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52, 655–709.

    Article  PubMed  CAS  Google Scholar 

  30. Carrell, R. W. and Boswell, D. R. (1990) Serpins: the superfamily of plasma serine proteinase inhibitors, in Proteinase Inhibitors (Barrett, A. J. and Salvesen, G., eds.), Leuven University Press, Leuven, pp. 403–420.

    Google Scholar 

  31. Carrell, R. W. and Travis, J. (1985) α1-antitrypsin and the serpins: variation and countervariation. Trends Biochem. Sci. 20–24.

    Google Scholar 

  32. Schapira, M., Agostini de, A., Schifferli, J. A., and Colman, R. W. (1985) Biochemistry and pathophysiology of human C1 inhibitor: Current issues. Complement 2, 111–126.

    PubMed  CAS  Google Scholar 

  33. Sim, R. B., Reboul, A., Arlaud, G. J., Villiers, C. L., and Colomb, M. G. (1979) Interaction of 125I-labelled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBS Lett. 97, 111–115.

    Article  PubMed  CAS  Google Scholar 

  34. Chan, J. Y. C., Burrowes, C. E., Habal, F. J., and Movat, H. Z. (1977) The inhibition of activated factor XII (Hageman factor) by antithrombin III: effect of other plasma proteinase inhibitors. Biochem. Biophys. Res. Commun. 74, 150–158.

    Article  PubMed  CAS  Google Scholar 

  35. Schapira, M., Scott, C. F., and Colman, R. W. (1982) Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 69, 462–468.

    Article  PubMed  CAS  Google Scholar 

  36. van der Graaf, F., Koedam, J. A., and Bouma, B. N. (1983) Inactivation of kallikrein in human plasma. J. Clin. Invest. 71, 149–158.

    Article  PubMed  Google Scholar 

  37. Pixley, R. A., Schapira, M., and Colman, R. W. (1985) The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 260, 1723–1729.

    PubMed  CAS  Google Scholar 

  38. Wuillemin, W. A., Minnema, M. C., Meijers, J. C. M., et al. (1995) Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 85, 1517–1526.

    PubMed  CAS  Google Scholar 

  39. Nuijens, J. H., Eerenberg-Belmer, A. J. M., Huijbregts, C. C. M., et al. (1989) Proteolytic inactivation of plasma C1-inhibitor in sepsis. J. Clin. Invest. 84, 443–450.

    Article  PubMed  CAS  Google Scholar 

  40. de Smet, B. J. G. L., De Boer, J. P., Agterberg, J., Rigter, G., Bleeker, W. K., Hack CE. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood (1993) 81, 56–61.

    PubMed  Google Scholar 

  41. Wuillemin, W. A., Bleeker, W. K., Agterberg, J., Rigter, G., Ten Cate, H., and Hack, C. E. (1996) Clearance of human factor XIa-inhibitor complexes in rats. Br. J. Haematol. 93, 950–954.

    Article  PubMed  CAS  Google Scholar 

  42. Wuillemin, W. A., Hack, C. E., Bleeker, W. K., Biemond, B. J., Levi, M., and ten Cate H. (1996) Inactivation of factor XIa in vivo: studies in chimpanzees and in humans. Thromb. Haemost. 76, 549–555.

    PubMed  CAS  Google Scholar 

  43. Nuijens, J. H., Huijbregts, C. C. M., Eerenberg, A. J. M., et al. (1988) Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 72, 1841–1848.

    PubMed  CAS  Google Scholar 

  44. Perlmutter, D. H., Glover, G. I., Rivetna, M., Schasteen, C. S., and Fallon, R. J. (1990) Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc. Natl. Acad. Sci. USA 87, 3753–3757.

    Article  PubMed  CAS  Google Scholar 

  45. Pizzo, S. V., Mast, A. E., Feldman, S. R., and Salvesen, G. (1988) In vivo catabolism of α1-antichymotrypsin is mediated by the serpin receptor which binds a1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim. Biophys. Acta 967, 158–162.

    Article  PubMed  CAS  Google Scholar 

  46. Kalter, E. S., Daha, M. R., Ten Cate, J. W., Verhoef, J., and Bouma, B. N. (1985) Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J. Infect. Dis. 151, 1019–1027.

    Article  PubMed  CAS  Google Scholar 

  47. Woo, P., Lachmann, P. J. L., Harrison, R. A., and Amos, N. (1985) Simultaneous turnover of normal and dysfunctional C1 Inhibitor as a probe of in vivo activation of Cl and contact activatable proteases. Clin. Exp. Immunol. 61, 1–8.

    PubMed  CAS  Google Scholar 

  48. Heda, G. D., Mardente, S., and Schmaier, A. H. Interferon gamma increases in vitro and in vivo expression of C1 inhibitor. Blood (1990) 75, 2401–2407.

    PubMed  CAS  Google Scholar 

  49. Carrell, R. W., Christey, P. B., and Boswell, D. R. (1987) Serpins: antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from amino acid sequences, in Thrombosis and Haemostasis (Verstraete, M., Vermylen, J., Lijnen, R., Arnout, J., eds.), Leuven University Press, Leuven, pp. 1–15.

    Google Scholar 

  50. Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365–376.

    Article  PubMed  CAS  Google Scholar 

  51. Brower, M. S. and Harpel, P. C. (1982) Proteolytic cleavage and inactivation of α2-plasmin inhibitor and C1-inactivator by human polymorphonuclear leucocyte elastase. J. Biol. Chem. 257, 9849–9854.

    PubMed  CAS  Google Scholar 

  52. Eldering, E., Huijbregts, C. M., Nuijens, J. H., Verhoeven, A. J, and Hack, C. E. (1993) Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils. J. Clin. Invest. 91, 1035–1043.

    Article  PubMed  CAS  Google Scholar 

  53. Quastel, M., Harrison, R., Cicardi, M., Alper, C. A., and Rosen, F. S. (1983) Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest. 71, 1041–1046.

    Article  PubMed  CAS  Google Scholar 

  54. Minta, J. O. (1981) The role of sialic acid in the functional activity and the hepatic clearance of C1-Inh. J. Immunol. 126, 245–249.

    PubMed  CAS  Google Scholar 

  55. Agostoni, A., Bergamaschini, L., Martignoni G, Cicardi M, and Marasini B. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann. Allergy (1980) 44, 299–301.

    PubMed  CAS  Google Scholar 

  56. Gadek, J. E., Hasea, S. W., Gelfand, J. A., et al. (1980) Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N. Engl. J. Med. 302, 542–546.

    Article  PubMed  CAS  Google Scholar 

  57. Bock, S. C., Skriver, K., Nielsen, E., et al. (1986) Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25, 4292–4301.

    Article  PubMed  CAS  Google Scholar 

  58. Hack, C. E., Ogilvie, A. C., Eisele, B., Eerenberg, A. J. M., Wagstaff, J., and Thijs, L. G. (1993) C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 19, 19–28.

    Article  Google Scholar 

  59. Hack, C. E. (1996) C1-inhibitor substitution therapy in septic shock or vascular leak syndrome. Biomed. Progress 9, 4–7.

    Google Scholar 

  60. Jansen, P. M., Eisele, B., De Jong, I. W., et al. (1998) Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J. Immunol. 160, 475–484.

    PubMed  CAS  Google Scholar 

  61. Rent, R., Myhrman, R., Fiedel, A., and Gewurz, H. (1976) Potentiation of C1 esterase inhibitor activity by heparin. Clin. Exp. Immunol. 23, 264–271.

    CAS  Google Scholar 

  62. Sim, R. B., Arlaud, G. J., and Colomb, M. G. (1980) Kinetics of reaction of human C1 inhibitor with human complement system protease C1r and C1s. Biochim. Biophys. Acta 612, 433–449.

    Article  PubMed  CAS  Google Scholar 

  63. Wuillemin, W. A., Te Velthuis, H., Lubbers, Y. T. P., De Ruig, C. P., Eldering, E., and Hack, C. E. (1997) Potentiation of C1 inhibitor by glycosaminoglycans. Dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J. Immunol. 159, 1953–1960.

    PubMed  CAS  Google Scholar 

  64. Wuillemin, W. A., Eldering, E., Citarella, F., De Ruig, C. P., Ten Cate H, and Hack, C. E. (1996) Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J. Biol. Chem. 271, 12913–12918.

    Article  PubMed  CAS  Google Scholar 

  65. Waytes, A. T., Rosen, F. S., and Frank, M. M. (1996) Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N. Engl. J. Med. 334, 1630–1634.

    Article  PubMed  CAS  Google Scholar 

  66. Bork, K. and Witzke, G. (1989) Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J. Allergy Clin. Immunol. 83, 677–682.

    Article  PubMed  CAS  Google Scholar 

  67. Cugno, M., Hack, C. E., De Boer, J. P., Eerenberg, A. J. M., Agostoni, A., and Cicardi, M. (1993) Generation of plasmin in association with contact system activation during attacks in hereditary angioneurotic edema. J. Lab. Clin. Med. 121, 38–43.

    PubMed  CAS  Google Scholar 

  68. Lopez-Trascasa, M., Moisy, M., Pirotzky, E., Blouguit, Y., Blanc, C., and Sobel, A. T. (1982) Isolation and characterization of a biologically active C2-derived oligopeptide. Mol. Immunol. 19, 1403–1410.

    Article  Google Scholar 

  69. Pixley, R. A., De La Cadena, R. A., Page, J. D., et al. (1992) Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am. J. Pathol. 140, 897–906.

    PubMed  CAS  Google Scholar 

  70. Pixley, R. A., De La Cadena, R., Page, J. D., et al. (1993) The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: in vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J. Clin. Invest. 91, 61–68.

    Article  PubMed  CAS  Google Scholar 

  71. Jansen, P. M., Pixley, R. A., Brouwer, M., et al. (1996) Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87, 2337–2344.

    PubMed  CAS  Google Scholar 

  72. Quezado, Z. M. A., Hoffman, W. D., Winkelstein, J. A., et al. (1994) The third component of complement protects against Escherichia coli Endotoxininduced shock and multiple organ failure. J. Exp. Med. 179, 569–578.

    Article  PubMed  CAS  Google Scholar 

  73. Fischer, M. B., Prodeus, A. P., Nicholson-Weller, A., et al. (1997) Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J. Immunol. 159, 976–982.

    PubMed  CAS  Google Scholar 

  74. Stevens, J. H., O’Hanley, P., Shapiro, J. M., et al. (1986) Effects of anti-05a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77, 1818–1826.

    Article  Google Scholar 

  75. Olson, L. M., Moss, G. S., Baukus, O., and Das Gupta, T. K. (1985) The role of C5 in septic lung injury. Ann. Surg. 202, 771–776.

    Article  PubMed  CAS  Google Scholar 

  76. Barton, P. A. and Warren, J. S. (1993) Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect Immun. 61, 1474–1481.

    PubMed  CAS  Google Scholar 

  77. Rabinovici, R., Yeh, C. G., Hillegass, L. M., et al. (1992) Role of complement in endotoxin/platelet activating factor-induced lung injury. J. Immunol. 149, 1744–1750.

    PubMed  CAS  Google Scholar 

  78. Scherer, R. U., Giebler, R. M., Schmidt, U., Paar, D., and Kox, W. J. (1996) The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. Semin. Thromb. Hemost. 22, 357–366.

    Article  PubMed  CAS  Google Scholar 

  79. Dickneite, G. (1993) Influence of C1-inhibitor on inflammation, Edema and Shock. Behring Inst. Mitt. 93, 299–305.

    PubMed  CAS  Google Scholar 

  80. Guerrero, R., Velasco, F., Rodriquez, M., et al. (1993) Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J. Clin. Invest. 91, 2754–2760.

    Article  PubMed  CAS  Google Scholar 

  81. Hack, C. E., Voerman, H. J., Eisele, B., et al. (1992) C1-esterase inhibitor substitution in sepsis. Lancet 339, 378.

    Article  PubMed  CAS  Google Scholar 

  82. Nürnberger, W., Göbel, U., Stannigel, H., Eisele, B., Janssen, A., and Delvos, U. C1-inhibitor concentrate for sepsis-related capillary leak syndrome. Lancet (1992) 339, 990.

    Article  PubMed  Google Scholar 

  83. Gaynor, E. R., Vitek, L., Sticklin, L., et al. (1988) The hemodynamic effects of treatment with interleukin-2 and lymphokine activated killer cells. Ann. Intern. Med. 109, 953–958.

    PubMed  CAS  Google Scholar 

  84. Ognibene, F. P., Rosenberg, S. A., Lotze, M., et al. (1988) Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94, 750–754.

    Article  PubMed  CAS  Google Scholar 

  85. Stieh, J., Harding, P., Scheewe, J., Dutschke, P., and Kramer, H. H. (1996) Capillary leak syndrome after open heart surgery for congenital heart defects: therapy with C1-inhibitor. Biomed Progress 9, 13–16.

    Google Scholar 

  86. Nurnberger, W., Michelmann, I., Petrik, K., et al. (1993) Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann. Hematol. 67, 17–21.

    Article  PubMed  CAS  Google Scholar 

  87. Damle, N. K. and Doyle, L. V. (1989) IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leakage syndrome. J. Immunol. 142, 2660–2669.

    PubMed  CAS  Google Scholar 

  88. Damle, N. K., Doyle, L. V., Bender, J. R., and Bradley, E. C. (1987) Interleukin-2 activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J. Immunol. 138, 1779–1785.

    PubMed  CAS  Google Scholar 

  89. Boccoli, G., Masciulli, R., Ruggeri, E. M., et al. (1990) Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res. 50, 5795–5800.

    PubMed  CAS  Google Scholar 

  90. Gemlo, B. T. (1988) Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 48, 5864–5867.

    PubMed  CAS  Google Scholar 

  91. Vachino., G., Gelfand, J. A., Atkins, M. B., Tamerius, J. D., Demchak, P., and Mier, J. W. (1991) Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): Binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 78, 2505–2513.

    Google Scholar 

  92. Baars, J. W., De Boer, J. P., Wagstaff, J., et al. (1992) Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br. J. Haematol. 82, 295–301.

    Article  PubMed  CAS  Google Scholar 

  93. Hack, C. E., Wagstaff, J. , Strack van Schijndel, R. J. M., et al. (1991) Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock. Thromb. Haemost. 65, 497–503.

    PubMed  CAS  Google Scholar 

  94. Ogilvie, A. C., Baars, J. W., Eerenberg, A. J. M., et al. (1994) A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2. Br. J. Cancer 69, 596–598.

    Article  PubMed  CAS  Google Scholar 

  95. Nurnberger, W. and Gobel, U. (1996) Capillary leak syndrome following bone marrow transplantation. Biomed. Prog. 9, 8–12.

    Google Scholar 

  96. Nurnberger, W., Heying, R., Burdach, S., and Gobel, U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann. Hematol. (1997) 75, 95–101.

    Article  PubMed  CAS  Google Scholar 

  97. Libby, P., Maroko, P. R., Bloor, C. M., Sobel, B. E., and Braunwald, E. (1973) Reduction of experimental myocardial infarction size by corticosteroid administration. J. Clin. Invest. 52, 599–607.

    Article  PubMed  CAS  Google Scholar 

  98. Entman, M. L., Michael, L., Rossen, R. D., et al. (1991) Inflammation in the course of early myocardial ischemia. FASEB J. 5, 2529–2537.

    PubMed  CAS  Google Scholar 

  99. Hill, J. H. and Ward, P. A. (1971) The phlogistic role of C3 leukotactic fragment in myocardial infarcts of rats. J. Exp. Med. 133, 885–900.

    Article  PubMed  CAS  Google Scholar 

  100. Vakeva, A., Laurila, P., and Meri, S. (1993) Regulation of complement membrane attack complex formation in myocardial infarction. Am. J. Pathol. 143, 65–75.

    PubMed  CAS  Google Scholar 

  101. Pinckard, R. N., O’Rourke, R. A., Crawford, M. H., Storrs, S. B., and Olson, M. S. (1980) Complement localization and mediation of ischemic injury in baboon myocardium. J. Clin. Invest. 66, 1050–1056.

    Article  PubMed  CAS  Google Scholar 

  102. McManus, L. M., Kolb, W. P., Crawford, M. H., O’Rourke, R. A., Grover, F. L., and Pinckard, R. N. (1983) Complement localization in ischemic baboon myocardium. Lab. Invest. 48, 436–447.

    PubMed  CAS  Google Scholar 

  103. Rossen, R. D., Swain, J. L., Michael, L. H., Weakley, S., Giannini, E., and Entman, M. L. (1985) Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury. Circ. Res. 57, 119–130.

    Article  PubMed  CAS  Google Scholar 

  104. Vakeva, A., Morgan, B. P., Tikkanen, I., Helin, K., Laurila, P., and Meri, S. (1994) Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am. J. Pathol. 144, 1357–1368.

    PubMed  CAS  Google Scholar 

  105. Schafer, H., Methey, D., Hugo, F., and Bhakdi, S. (1986) Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J. Immunol. 137, 1945–1949.

    PubMed  CAS  Google Scholar 

  106. Hugo, F., Hamdoch, T., Methey, D., Schafer, H., and Bhakdi, S. (1990) Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin. Exp. Immunol. 81, 132–136.

    Article  PubMed  CAS  Google Scholar 

  107. Crawford, M. H., Grover, F. L., Kolb, W. P., et al. (1988) Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78, 1449–1458.

    Article  PubMed  CAS  Google Scholar 

  108. Vakeva, A., Laurila, P., and Meri, S. (1992) Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab. Invest. 67, 608–616.

    PubMed  CAS  Google Scholar 

  109. Langlois, P. F. and Gawryl, M. S. (1988) Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis 70, 95–105.

    Article  PubMed  CAS  Google Scholar 

  110. Yasuda, M., Takeuchi, K., Hiruma, M., et al. (1990) The complement system in ischemic heart disease. Circulation 81, 156–163.

    Article  PubMed  CAS  Google Scholar 

  111. Amsterdam, E. A., Stahl, G. L., Pan, H. L., Rendig, S. V., Fletcher, M. P., and Longhurst, J. C. (1995) Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am. J. Physiol. 268, H448–H457.

    Google Scholar 

  112. Giclas, P. C., Pinckard, R. N., and Olson, M. S. (1979) In vitro activation of complement by isolated human heart subcellular membranes. J. Immunol. 122, 146–151.

    PubMed  CAS  Google Scholar 

  113. Rossen, R. D., Michael, L. H., Kagiyama, A., et al. (1988) Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo. Circ. Res. 62, 572–584.

    Article  PubMed  CAS  Google Scholar 

  114. Ito, B. R., Roth, D. M., and Engler, R. L. (1990) Thromboxane A2 and peptidoleukotrienes contribute to myocardial ischemia and contractile dysfunction in response to intracoronary infusion of C5a in pigs. Circ. Res. 66, 596–607.

    Article  PubMed  CAS  Google Scholar 

  115. Hachfeld del Balzo, U. H., Levi, R., and Polley, M. J. (1985) Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc. Natl. Acad. Sci. USA 82, 886–890.

    Article  Google Scholar 

  116. Martin, S. E., Chenoweth, D. E., Engler, R. L., Roth, D. M., and Longhurst, J. C. (1988) C5a decreases regional coronary blood flow and myocardial function in pigs: Implications for a granulocyte mechanism. Circ. Res. 63, 483–491.

    Article  PubMed  CAS  Google Scholar 

  117. Maroko, P. R., Carpenter, C. B., Chiariello, M., et al. (1978) Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J. Clin. Invest. 61, 661–670.

    Article  PubMed  CAS  Google Scholar 

  118. Dreyer, W. J., Michael, L. H., Nguyen, T., et al. (1992) Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemiareperfusion injury. Circ. Res. 71, 1518–1524.

    Article  PubMed  CAS  Google Scholar 

  119. Weisman, H. F., Bartow, T., Leppo, M. K., et al. (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249,146–151.

    Article  PubMed  CAS  Google Scholar 

  120. Buerke, M., Murohara, T., and Lefer, A. M. (1995) Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91, 393–402.

    Article  PubMed  CAS  Google Scholar 

  121. Murohara, T., Guo, J.-P., Delyani, J. A., Lefer, A. M. (1998) Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion. Methods Find. Exp. Clin. Pharmacol. 17, 499–507.

    Google Scholar 

  122. Horstick, G., Heimann, A., Gotze, O., et al. (1997) Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 95, 701–708.

    Article  PubMed  CAS  Google Scholar 

  123. Ruud, T. E., Aasen, A. O., Pillgram-Larsen, J., and Stadaas, J. O. (1986) Effects on peritoneal proteolysis and hemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis. Scand. J. Gastroenterol. 21, 1018–1024.

    Article  PubMed  CAS  Google Scholar 

  124. Vesentini, S., Benetti, L., Bassi, C., et al. (1993) Effects of choline-esterase inhibitor in experimental acute pancreatitis in rats. Preliminary results. Int. J. Pancreatol. 13, 217–220.

    PubMed  CAS  Google Scholar 

  125. Yamaguchi, H., Weidenbach, H., Luhrs, H., Lerch, M. M., Dickneite, G., and Adler, G. (1997) Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut 40, 531–535.

    PubMed  CAS  Google Scholar 

  126. Salvatierra, A., Velasco, F., Rodriguez, M., et al. (1997) C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. Am. J. Respir. Crit. Care Med. 155, 1147–1154.

    PubMed  CAS  Google Scholar 

  127. Heckl-Ostreicher, B., Wosnik, A., and Kirschfink, M. (1996) Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation 62, 1693–1696.

    Article  PubMed  CAS  Google Scholar 

  128. Dalmasso, A. P. and Platt, J. L. (1993) Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 56, 1171–1176.

    Article  PubMed  CAS  Google Scholar 

  129. Khorram-Sefat, R., Goldmann, C., Radke, A., et al. (1998) The therapeutic effect of C1-inhibitor on gut-derived bacterial translocation after thermal injury. Shock 9, 101–108.

    Article  PubMed  CAS  Google Scholar 

  130. Henze, U., Lennartz, A., Hafemann, B., Goldmann, C., Kirkpatrick, C. J., and Klosterhalfen, B. (1997) The influence of the C1-inhibitor BERINERT and the protein-free haemodialysate ACTIHAEMYL20% on the evolution of the depth of scald burns in a porcine model. Burns 23, 473–477.

    Article  PubMed  CAS  Google Scholar 

  131. Kochilas, L., Campbell, B., Csalia, R., and Lefer, A. M. (1997) Beneficial effects of C1 esterase inhibitor in murine traumatic shock. Shock 8, 165–169.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Erik Hack
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    John D. Lambris PhD

  2. University of Colorado Health Sciences Center, Denver, CO, USA

    V. Michael Holers MD

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Hack, C.E. (2000). The Regulation of C1 Activation and Its Role in Disease. In: Lambris, J.D., Holers, V.M. (eds) Therapeutic Interventions in the Complement System. Contemporary Immunology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-017-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-017-9_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9612-3

  • Online ISBN: 978-1-59259-017-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation